NuvOx Therapeutics, Inc. plans to list on the NYSE American under the symbol NUOX. It filed a Form S-1 registration statement for an initial public offering on July 17, 2026. As of November 8, 2026, its registration is amended and on file (Form S-1/A, October 29, 2026).
Sell to companies like NuvOx Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
NuvOx Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-17. It has amended it 3 times. As of its latest filing, on 2026-10-29, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
Also on the record for NuvOx Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 22, 2024 | Form D, private offering | $235K sold | Form D page | Source |
Check before you invest in NuvOx Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on NuvOx Therapeutics, Inc. and the records around it.
Also filing to list on the NYSE American
IPO filings on the NYSE American in Q4 2026, newest first.
- Ambitious Entertainment, Inc. (Oct 2026)
- Neuro Spectrum Insights, Inc. (Oct 2026)
Watch NuvOx Therapeutics, Inc.
Get an email when NuvOx Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NuvOx Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NuvOx Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NuvOx Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
We intend to apply to list our common stock on the NYSE American under the symbol “NUOX.” This offering is contingent upon final approval by the NYSE American of our listing.From the S-1/A filed 2026-10-29
Shares offered
(2) The pro forma as adjusted balance sheet data reflects the items described in footnote (1) above and gives effect to our receipt of estimated net proceeds from the sale of 2,860,000 shares of common stock that we are offering in this offering at an assumed initial public offering price of the common stock of $7.00 per share, the midpoint of the price range on the cover page of this prospectus, and our receipt of approximately $17.4 million in net proceeds after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, as well as (i) an elimination of $929 thousand of deferred financing cost from assets and the reclassification of this…From the S-1/A filed 2026-10-29
Use of proceeds
We expect to use the net proceeds from this offering as follows:From the S-1/A filed 2026-10-29
Net loss or income
We incurred net losses of $7.0 million and $13.6 million for the nine months ended September 30, 2026 and September 30, 2025, respectively, and $16.6 million and $6.6 million for the years ended December 31, 2025 and December 31, 2024, respectively.From the S-1/A filed 2026-10-29
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-07-17 | Registration statement filed | S-1 |
| 2026-09-16 | Registration statement amended | S-1/A |
| 2026-10-13 | Registration statement amended | S-1/A |
| 2026-10-29 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for NuvOx Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.